Allogeneic Cell Therapy for Difficult-to-Treat IBD
Official title: Development of a Novel, Allogeneic Cell Therapy for Difficult to Treat IBD
Funded at Celdara Medical, LLC · NIH-11312520 · Data updated 2026-11-12
A new allogeneic cell therapy is being developed to help adults with stubborn inflammatory bowel disease who have not responded well to other treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celdara Medical, LLC NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $356,328 |
| NIH project number | 1R43DK143897-01A1 |
| Project ID | NIH-11312520 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21+) with active or difficult-to-treat IBD who have not responded adequately to standard therapies.
✕Less likely to help
Patients without IBD or those who have already achieved remission with existing treatments may not benefit.
What this research studies
This project aims to create a cell-based therapy using donor cells to reduce intestinal inflammation in adults with Crohn's disease or ulcerative colitis. The approach focuses on modulating immune responses and restoring balance in gut tissues. If successful, it could offer a new option for patients who have limited treatment choices and ongoing symptoms.
Why it matters
Potential benefit: If successful, patients with difficult-to-treat IBD may experience reduced inflammation and improved symptoms.
How similar studies have gone: Other cell-based therapies have shown promise in inflammatory conditions, but this specific allogeneic approach for difficult-to-treat IBD is still exploratory.
Where this research is happening
-
Celdara Medical, LLC
Lebanon, United States Active
Researchers
- Principal investigator: Cooper, Colleen Doyle — Celdara Medical, LLC
- Study coordinator: Cooper, Colleen Doyle
Related research
Other NIH-funded projects on the same topics.
-
Engineered regulatory T cells as a therapy for Gaucher disease
A new cell-based therapy using engineered regulatory T cells to help people with Gaucher disease, a type of lysosomal storage disorder.
-
Precision CAR-NK therapy to selectively remove autoreactive B cells in autoimmune diseases
A new, targeted cell therapy aims to remove disease-causing B cells in lupus while preserving the rest of the immune system.
-
Immunotherapy for Osteomyelitis: a new IL-2 based treatment
A new treatment approach is being explored to help bone infections like osteomyelitis by using a specialized immune-boosting agent to enhance the body’s own defense against bacteria.
-
CM-HZ01: a new high-boost IL-2 therapy for advanced melanoma
A new IL-2 based treatment called CM-HZ01 is being developed to help people with metastatic melanoma by steering the immune system toward stronger anti-tumor activity with potentially fewer side effects.
-
Engineered regulatory immune cells to protect nerves in ALS
Engineered regulatory immune cells (CAR Tregs) that seek out misfolded SOD1 and calm inflammation around motor neurons in people with ALS.
-
Using engineered immune cells to treat ALS
This study is exploring a new way to help people with ALS by using specially designed immune cells to target harmful proteins in the body, with the hope of reducing inflammation and slowing down the disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.